Monoclonal Antibodies Neutralize Pathogenic Autoantibodies

Steps:

• Identify the problem: In myasthenia gravis, autoantibodies bind and block ACh receptors on muscle cells, impairing nerve signaling.
• Determine treatment goal: Short-term injection must rapidly reduce circulating autoantibodies to restore receptor function.
• Infer monoclonal antibody role: These lab-produced antibodies specifically target and bind to the harmful autoantibodies for clearance.
• Conclude target: The monoclonal antibodies bind the disease-causing antibodies, not the receptors or cells directly.

Why A is correct:

• Monoclonal antibodies are engineered to specifically recognize and neutralize pathogenic immunoglobulins, as defined in immunotherapy protocols for autoimmune diseases like myasthenia gravis.

Why the others are wrong:

• B: Targeting ACh receptors would block them further, exacerbating muscle weakness.
• C: No option provided, so invalid.
• D: Plasma cells produce antibodies long-term; short-term treatment focuses on circulating antibodies, not depleting producers.

Final answer: A